



8th Annual

LEAD 2026

LEADERSHIP
EMPOWERMENT
DEVELOPMENT

Enriching Experiences for Leaders in Hematology and Oncology

**SEPT
18-19,
2026**

Updates in Lung Cancer

Susan Scott, MD

Non-Small Cell Lung Cancer

Disclosures

Research funding (direct to institution)

Consultant: AstraZeneca, Johnson & Johnson Research funding (direct to institution):
Black Diamond Therapeutics, Nuvalent

Consultant: Boehringer Ingelheim, Daiichi Sankyo

Trends in Non-Small Cell Lung Cancer 2026

Precision

- Novel therapies/regimens developing within genomic driver-defined subsets of NSCLC
- Refined selection within driver-defined subsets

Broadening indications/applications

- Early-stage use of targeted therapy
- 1L combinations

Drug design

- Higher selectivity > delayed resistance
- Minimized off target effect > improved toxicity profile

Updates in Precision Lung Cancer Care 2024–2026

Practice-changing new drugs/regimens

EGFR exon 19/21

- Osimertinib + chemotherapy
- Amivantamab + lazertinib
- Consolidation osimertinib

EGFR ex20

- Sunvozertinib

ALK

- Adjuvant alectinib

RET

- Adjuvant selpercatinib

HER2


- Zongertinib
- Sevabertinib

ROS1

- Taletrectinib


Non-AGA — Telisotuzumab vedotin for MET 3+

EGFRm NSCLC: Intensification of 3G EGFR TKI




Osimertinib + Chemotherapy

- FLAURA-2
- HR PFS 0.62
- mPFS 25.5 m




Lazertinib + Amivantamab

- MARIPOSA
- HR PFS 0.70
- mPFS 23.7 m



Osimertinib + Ramucirumab

- RAMOSE
- HR PFS 0.55
- mPFS 24.8 m



Osimertinib + Local Consolidation


- NorthSTAR
- HR PFS 0.66
- mPFS 25.3 m

ACROSS 2: HR PFS 0.55

EGFRm with tumor suppressor co-mutation
Aumolertinib + chemo vs aumolertinib

EGFR: Intensification prolongs OS

FLAURA2




	Median OS	HR
Osi/chemo	47.5 (41.0 – NC)	HR 0.77 (0.57 – 0.97)
Osi	37.6 (33.2 – 43.2)	

Key Toxicities:

- Cytopenias
- Rash
- Diarrhea

MARIPOSA



	Median OS	HR
Ami/Laz	NE (42.9 – NE)	HR 0.75 (0.61 – 0.92)
Osi	36.7 (33.4 – 41.0)	




Parametric Model	Amivantamab-lazertinib projected median overall survival (95% CI), mo
Exponential	55.3 (51.8–58.8)
Weibull	50.4 (47.5–53.2)
Generalized gamma	49.5 (46.9–52.2)
Log-logistic	52.3 (49.1–55.5)
Log-normal	57.7 (53.7–61.8)

Key Toxicities:

- Rash
- Paronychia
- Edema

EGFR: Datopotamab deruxtecan



EGFRm NSCLC after TKI and chemo



- Key Toxicities:**
- Stomatitis
 - Ocular
 - ILD


Advanced EGFRm NSCLC Management in 2026

Exon 19 deletion, exon 21 L858R substitution




EGFR: Consolidation Osimertinib

LAURA



EGFR: Consolidation Osimertinib

LAURA




Key Toxicities:

- ILD/Pneumonitis after chemoRT

ALK: Adjuvant alectinib


ALINA



ALK: Adjuvant alectinib

ALINA

Patients with Stage II or IIIA Disease



No. at Risk

Alectinib	116	111	111	107	67	49	35	21	10	3
Chemotherapy	115	102	88	79	48	35	23	17	10	2


Median Disease-free Survival (95% CI)
mo

Alectinib	Not reached
Chemotherapy	44.4 (27.8–NE)

Hazard ratio for disease recurrence or death, 0.24 (95% CI, 0.13–0.45)
 $P < 0.001$


ALK: Adjuvant alectinib

ALINA



ALK: Adjuvant alectinib


ALINA



RET: Adjuvant selpercatinib LIBRETTO-432

3 years of treatment

A Event-free Survival in the Primary Analysis Population



	No. of Patients	No. of Events	Median Event-free Survival (95% CI) mo
Selpercatinib	54	4	NE (33.5 to NE)
Placebo	55	19	31.8 (18.4 to NE)

Hazard ratio for disease recurrence, progression, or death, 0.17 (95% CI, 0.06–0.51)
P<0.001

No. at Risk

Selpercatinib	54	49	45	45	37	36	27	27	22	21	15	12	7	0	0
Placebo	55	54	47	44	28	27	22	21	16	15	8	6	4	2	0


Pending review by FDA

HER2: Zongertinib

Beamion LUNG-1

Cohort 1:
Pretreated NSCLC w *HER2* TKD mutation

Progression-free Survival




ORR: 71%
mDOR: 8.5 mo
mPFS: 12.4 mo
mOS: 24.8 mo

Key Toxicities:

- Diarrhea
- Rash
- Dose reduction 16%
- Discontinuation 9%

Cohort 2:
Treatment-naïve NSCLC w *HER2* TKD mutation



ORR: 76%
mDOR: 15.2 mo
mPFS: 14.4 mo

HER2: Sevabertinib

SOHO LUNG-1

Cohort D: n=70
Pretreated NSCLC w *HER2* activating mutation


ORR: 71%
mDOR: 9.2 mo
mPFS: 8.3 mo

Cohort F: n=73
Treatment-naïve NSCLC w *HER2* activating mutation

ORR: 71%
mDOR: 11.0 mo
mPFS: NR

Ph 3 SOHO-Lung 02 ongoing

C Progression-free Survival



No. at Risk

Cohort D	81	66	45	32	25	11	9	7	3	1	1	0
Cohort E	55	38	23	15	11	3	1	0				
Cohort F	73	63	41	23	12	0						

Key Toxicities:



- Diarrhea*
- Rash
- Dose reduction 26%
- Discontinuation 5%

ROS1: Taletrectinib

TRUST-I, TRUST-II

Active against G2032R

Treatment-naïve n=103



ORR: 90%
mDOR: 49.7 mo
mPFS: 49.6 mo
mOS: NR

Key Toxicities:

- Diarrhea, N/V
- ALT/AST elevation
- Dizziness
- Hyperuricemia

Updates in Precision Lung Cancer Care 2024–2026

Practice-changing new drugs/regimens

EGFR exon 19/21

- Osimertinib + chemotherapy
- Amivantamab + lazertinib
- Consolidation osimertinib

EGFR ex20

- Sunvozertinib

ALK

- Adjuvant alectinib

RET

- Adjuvant selpercatinib

HER2

- Zongertinib
- Sevabertinib

ROS1

- Taletrectinib

Non-AGA — Telisotuzumab vedotin for MET 3+

Trends in Non-Small Cell Lung Cancer 2026

Precision

- Novel therapies/regimens developing within genomic driver-defined subsets of NSCLC
- Refined selection within driver-defined subsets (eg EGFR nonclassical, HER2 TKDm, acquired MOR)

Broadening indications/applications

- Early-stage use of targeted therapy
- 1L combinations

Drug design

- Higher selectivity > delayed resistance
- Minimized off target effect > improved toxicity profile